We've done it before. And we’ll do it again. Joint Nordic negotiations are here to stay.
Therefore, procurement organisations in Iceland, Norway, Sweden and Denmark have agreed on common guidelines and criteria for joint price negotiations for new medicines.
The new principles are based on experience gained by the countries from the joint Nordic negotiations that have already taken place.
“In the joint Nordic strategy we launched in spring 2023, our ambition is to strengthen joint negotiations for new medicines. Therefore, an entirely natural next step is to develop common guidelines for our future negotiations. This will send a clear signal to benefit our cooperation partners,” says Flemming Sonne, CEO of Amgros.
The four countries have already completed joint price negotiations for the gene therapies, Zynteglo and Libmeldy. This experience shows that there are clear advantages in joint negotiations.
“Joint negotiations between countries create a larger market. This can make it more attractive for our suppliers, because they can increase their opportunities to introduce new medicines to the whole Nordic market at the same time. As citizens of small countries, joint negotiations are a clear advantage for Iceland, Denmark, Sweden and Norway,” says Hulda Harðardóttir, Project Manager for the Pharmaceutical Procurement Department, Landspítali, National University Hospital of Iceland.